Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Viera Kupčová, Jan Šperl, Anne Pannier, Paul Jordan, Frank C. Dougherty & Bruno Reigner. (2008) The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.. Current Medical Research and Opinion 24:7, pages 1943-1950.
Read now
Read now
Articles from other publishers (26)
Ken Aizawa, Ryohei Kawasaki, Yoshihito Tashiro, Yasushi Shimonaka & Michinori Hirata. (2018) Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease. BMC Nephrology 19:1.
Crossref
Crossref
Gemma Reverter-Branchat, Rosa Ventura, Mohammed Ezzel Din, Julián Mateus, Carme Pedro & Jordi Segura. (2018) Detection of erythropoiesis-stimulating agents in a single dried blood spot. Drug Testing and Analysis 10:10, pages 1496-1507.
Crossref
Crossref
Kenichi Serizawa, Kenji Yogo, Yoshihito Tashiro, Ryohei Kawasaki, Koichi Endo, Yasushi Shimonaka & Michinori Hirata. (2017) Epoetin beta pegol ameliorates flow-mediated dilation with improving endothelial nitric oxide synthase coupling state in nonobese diabetic rats. Cardiovascular Therapeutics 35:2, pages e12250.
Crossref
Crossref
Keitaro NishizawaToshiyuki YanoMasaya TannoTakayuki MikiAtsushi KunoToshiyuki TobisawaMakoto OgasawaraShingo MuratsubakiKouhei OhnoSatoko IshikawaTetsuji Miura. (2016) Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease–Induced Enlargement of Myocardial Infarct Size. Hypertension 68:3, pages 697-706.
Crossref
Crossref
Mark J. Koury. (2016) Tracking erythroid progenitor cells in times of need and times of plenty. Experimental Hematology 44:8, pages 653-663.
Crossref
Crossref
Ken Aizawa, Ryohei Kawasaki, Yoshihito Tashiro, Michinori Hirata, Koichi Endo & Yasushi Shimonaka. (2016) Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. International Journal of Hematology 104:2, pages 182-189.
Crossref
Crossref
Norio Suzuki & Masayuki Yamamoto. (2015) Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflügers Archiv - European Journal of Physiology 468:1, pages 3-12.
Crossref
Crossref
Tetsuya Furukawa, Kazuyoshi Okada, Masanori Abe, Ritsukou Tei, Osamu Oikawa, Noriaki Maruyama & Takashi Maruyama. (2015) Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. International Journal of Molecular Sciences 16:12, pages 30181-30189.
Crossref
Crossref
Kenichi Serizawa, Kenji Yogo, Yoshihito Tashiro, Ken Aizawa, Ryohei Kawasaki, Michinori Hirata & Koichi Endo. (2015) Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats. European Journal of Pharmacology 767, pages 10-16.
Crossref
Crossref
Sayaka Takahashi, Yoshiko Tanaka, Mari Takano, Keiko Suzuki, Mio Ueda, Yukiko Shimamoto & Kosaku Nitta. (2015) Hemoglobin Level Stability after a Switch from Darbepoetin Alfa to Epoetin Beta Pegol for the Treatment of Renal Anemia in Hemodialysis Patients. International Journal of Clinical Medicine 06:09, pages 652-660.
Crossref
Crossref
Matthias Vogel, Mike Blobel, Andreas Thomas, Katja Walpurgis, Wilhelm Schänzer, Christian Reichel & Mario Thevis. (2014) Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatography–Mass Spectrometry. Analytical Chemistry 86:24, pages 12014-12021.
Crossref
Crossref
Ken Aizawa, Yoshihito Tashiro, Michinori Hirata, Satoshi Takeda, Ryohei Kawasaki & Koichi Endo. (2014) Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats. Journal of Nephrology 27:4, pages 395-401.
Crossref
Crossref
Yusuke Sasaki, Mariko Noguchi-Sasaki, Yukari Matsuo-Tezuka, Yuki Matsumoto-Omori, Mitsue Kurasawa, Keigo Yorozu & Yasushi Shimonaka. (2014) Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. International Journal of Hematology 99:5, pages 561-569.
Crossref
Crossref
Jieun OhKwon-Wook JooHo-Jun ChinDong-Wan ChaeSung-Gyun KimSoo Jin KimWookyung ChungSejoong KimWooseong HuhHa Young OhBum Soon ChoiChul-Woo YangSuhnggwon Kim. (2014) Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis. Journal of Korean Medical Science 29:1, pages 76.
Crossref
Crossref
Teruhiko Maeba, Ryo Yoshizawa & Shigeru Owada. (2013) Long-term effect of CERA (continuous erythropoietin receptor activator) administered once every 2 weeks in hemodialysis patients with anemia. Nihon Toseki Igakkai Zasshi 46:10, pages 999-1006.
Crossref
Crossref
Naoaki Hayama, Satoshi Kurihara, Chikara Ishihara, Michiko Aoki & Yasuhiko Iino. (2013) Evaluation of anemia and the iron dynamics after administration of epoetin beta pegol(C.E.R.A.). Nihon Toseki Igakkai Zasshi 46:8, pages 707-713.
Crossref
Crossref
Roberto Minutolo, Giuseppe Conte, Mario Cozzolino, Pasquale Polito, Carlo Manno, Biagio R. Di Iorio, Domenico Santoro, Marina Di Luca, Felice Nappi, Sandro Feriozzi, Ferdinando C. Sasso & Luca De Nicola. (2013) Conversion from Epoetin and Darbepoetin to C.E.R.A. in Non-Dialysis CKD Patients: A Multicenter Italian Prospective Study in Nephrology Practice. Blood Purification 36:2, pages 69-77.
Crossref
Crossref
John K. Leypoldt, Mahmoud Loghman‐Adham, Paul Jordan & Bruno Reigner. (2011)
Effect of hemodialysis and hemofiltration on plasma
C.E.R.A
. concentrations
. Hemodialysis International 16:1, pages 20-30.
Crossref
Crossref
Peter D. Yorgin & Joshua Zaritsky. 2012. Pediatric Dialysis. Pediatric Dialysis
531
568
.
TOSHIAKI TAKAHASHI, NOBUYUKI YAMAMOTO, TOMOHIDE TAMURA, HIDEO KUNITOH, YUTAKA NISHIWAKI & SHUNICHI NEGORO. (2011) Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. Oncology Letters 2:6, pages 1033-1040.
Crossref
Crossref
B. Knebelmann. (2009) Stabilité de l’hémoglobine : résultats d’essais cliniques. Néphrologie & Thérapeutique 5:5, pages 15-20.
Crossref
Crossref
Amir Kazory & Edward A. Ross. (2009) Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?. Journal of the American College of Cardiology 53:8, pages 639-647.
Crossref
Crossref
Tejas PatelAjay K. Singh. (2009) Treatment of Anemia Associated with Chronic Kidney Disease with Methoxy Polyethylene Glycol-Epoetin Beta. Clinical Medicine. Therapeutics 1, pages CMT.S3339.
Crossref
Crossref
Sameer Doshi, Juan Jose Perez-Ruixo, Graham R. Jang & Andrew T. Chow. 2009. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Erythropoietins, Erythropoietic Factors, and Erythropoiesis
199
223
.
&NA;. (2008) Methoxy polyethylene glycol-epoetin beta: a guide to its use in anaemia associated with chronic kidney disease. Drugs & Therapy Perspectives 24:11, pages 1-5.
Crossref
Crossref
Esther Bouman-Thio, Kari Franson, Bruce Miller, John Getsy, Adam Cohen, Stephen A. Bai, Jennifer Yohrling, Bart Frederick, Stanley Marciniak, Qun Jiao, Haishan Jang, Hugh Davis & Jacobus Burggraaf. (2008) A Phase I, Single and Fractionated, Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects. The Journal of Clinical Pharmacology 48:10, pages 1197-1207.
Crossref
Crossref